Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anil Bioplus will invest Rs1.5bn ($28m) to construct a greenfield manufacturing facility at Halol, India, to manufacture enzymes and bio-chemical products.
Subscribe to our email newsletter
The company has already purchased land and is planning to begin the work from November 2012.
The company will produce hi-tech Active Pharma Ingredients (APIs), specialty enzymes for pharmaceutical industries using fermentation facilities with downstream processing.
The gluconates and enzymes products produced will meet both the domestic as well as the international market needs, according to the company.
Anil Bioplus chairman Amol Sheth said the new facility will have an ultra-tech R&D facility, which will focus on pure research, process development and application development.
”Constant focus on R&D and introduction of innovative value-added products have always been the unique selling propositions of the Anil Group,” Sheth added.
”On completion of this project, Anil Bioplus is expected to achieve a turnover of Rs 400 crore in three years."
The project is expected to expand company’s existing product line and increase its products range with the addition of new enzymes and varieties of gluconates.